By By Denny Jacob
Passage Bio, a clinical-stage genetic medicines company, has reported positive results from the initial safety and biomarket data of PBFT02, a groundbreaking treatment for dementia. As a result, shares of Passage Bio have surged by 29% in premarket trading, reaching 98 cents.
A Glimpse into the Clinical Trial
The data released by Passage Bio pertains to three patients from Cohort 1 who are part of an ongoing Phase 1/2 clinical trial. PBFT02, a gene therapy designed to address progranulin deficiency in frontotemporal dementia with granulin mutations, has shown remarkable potential in these early stages.
Promising Signs for Multiple Diseases
Chief Medical Officer Mark Forman expressed his enthusiasm, stating, “These data not only surpass our expectations based on preclinical non-human primate models but also validate the compelling potential of PBFT02 to address progranulin deficiency.” Forman’s statement highlights the immense promise that this treatment holds for patients suffering from various conditions.
Passage Bio is actively exploring the potential of PBFT02 in treating multiple diseases, such as FTD-C9orf72, amyotrophic lateral sclerosis, and Alzheimer’s disease. The initial data from the clinical trial of PBFT02 for frontotemporal dementia with granulin mutations has paved the way for broader applications in the field of neurological disorders.
In a year where Passage Bio’s stocks have faced a decline of 45%, this news brings hope and renewed confidence in the company’s prospects.
Comments